Share
clock Created with Sketch.
18/07/16
19:45
Share
Originally posted by cafa
↑
'If you are a government or health insurer, why wouldn't you mandate SIRT if option #2 was the result? '
4$ - I don't think these folks mandate any treatment. The medical profession will establish a standard of care and then there is pressure on the medcos to seriously consider the options.
I would agree that option 2, should be a no brainer for SIRT. It should become the SOC, and if SIRT yields an OS of 4 months more than sorafenib, which I believe it will, then SIRT would become SOC very quickly. IMO. However we must await the Asian trial as well, due to the different nature of the HCC compared to that found in France. A good result in Asia should allow SIRT to become SOC across the world for HCC, and then we just need the overall OS data from the 3 big mCRC trials in 2017.
Still holding my breath for an ethics approval for a lung cancer trial. Longer term, but very exciting, and then maybe another organ to boot.
PS are we going to run the lotto for the year end numbers?
Expand
"PS are we going to run the lotto for the year end numbers?"
Yep - I will get the thread started soon. We should get very close to nailing the NSV number given the dosage announcement but NPAT is always a bit of raffle.